The Valley Desk

NCT01039207 · Interventional trial

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Overall registry status Completed

Phase 2

Conditions Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov